An industry leader, we are dedicated to the science and research of regenerative medicine and its potential by supplying physicians with the best products on the market to treat their patients.
Organicell’s Osteoarthritis Treatment Zofin IND Gets FDA Greenlight
Organicell Regenerative Medicine (OTCPK:BPSR) announces that the U.S. FDA has approved the Investigational New Drug (IND) application for its lead product, Zofin, in the treatment of knee osteoarthritis.
The approved trial design, which will begin in Q2 of this year, will be a double blinded, placebo-controlled, phase I/II trial investigating the safety and potential efficacy of Zofin for patients suffering with knee osteoarthritis.
Zofin is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent.